Literature DB >> 18827143

ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth.

.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18827143     DOI： 10.1097/AOG.0b013e31818b1ff6

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN： 0029-7844            Impact factor:   7.661


× No keyword cloud information.
  31 in total

1.  Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle.

Authors:  Ruben J Kuon; Shao-Qing Shi; Holger Maul; Christof Sohn; James Balducci; William L Maner; Robert E Garfield
Journal:  Am J Obstet Gynecol       Date:  2010-05       Impact factor: 8.661

2.  17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length.

Authors:  Vincenzo Berghella; Dana Figueroa; Jeff M Szychowski; John Owen; Gary D V Hankins; Jay D Iams; Jeanne S Sheffield; Annette Perez-Delboy; Deborah A Wing; Edwin R Guzman
Journal:  Am J Obstet Gynecol       Date:  2010-04       Impact factor: 8.661

3.  Hydroxyprogesterone caproate injection (makena) one year later: to compound or not to compound that is the question.

Authors:  Yesha Patel; Martha M Rumore
Journal:  P T       Date:  2012-07

4.  Laparoscopic placement of cervical cerclage.

Authors:  Olga A Tusheva; Sarah L Cohen; Thomas F McElrath; Jon I Einarsson
Journal:  Rev Obstet Gynecol       Date:  2012

5.  A national survey examining obstetrician perspectives on use of 17-alpha hydroxyprogesterone caproate post-US FDA approval.

Authors:  Andrei Rebarber; Nathan Fox; Chad K Klauser; Daniel Saltzman; Ashley S Roman
Journal:  Clin Drug Investig       Date:  2013-08       Impact factor: 2.859

Review 6.  Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.

Authors:  Maisa Feghali; Raman Venkataramanan; Steve Caritis
Journal:  Semin Perinatol       Date:  2014-09-23       Impact factor: 3.300

7.  Patient characteristics associated with 17-alpha hydroxyprogesterone caproate use among a high-risk cohort.

Authors:  Amy L Turitz; Jamie A Bastek; Stephanie E Purisch; Michal A Elovitz; Lisa D Levine
Journal:  Am J Obstet Gynecol       Date:  2015-10-28       Impact factor: 8.661

8.  Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.

Authors:  Steve N Caritis; Raman Venkataramanan; Elizabeth Thom; Margaret Harper; Mark A Klebanoff; Yoram Sorokin; John M Thorp; Michael W Varner; Ronald J Wapner; Jay D Iams; Marshall W Carpenter; William A Grobman; Brian M Mercer; Anthony Sciscione; Dwight J Rouse; Susan Ramin
Journal:  Am J Obstet Gynecol       Date:  2013-10-07       Impact factor: 8.661

9.  Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis.

Authors:  Alison G Cahill; Anthony O Odibo; Aaron B Caughey; David M Stamilio; Sonia S Hassan; George A Macones; Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2010-01-15       Impact factor: 8.661

10.  The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies.

Authors:  Cynthia Gyamfi; Amanda L Horton; Valerija Momirova; Dwight J Rouse; Steve N Caritis; Alan M Peaceman; Anthony Sciscione; Paul J Meis; Catherine Y Spong; Mitchell Dombrowski; Baha Sibai; Michael W Varner; Jay D Iams; Brian M Mercer; Marshall W Carpenter; Julie Lo; Susan M Ramin; Mary Jo O'Sullivan; Menachem Miodovnik; Deborah Conway
Journal:  Am J Obstet Gynecol       Date:  2009-08-29       Impact factor: 8.661
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.